Scientific Presentations

2017 Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting

ORAL PRESENTATION

Slides: SITC 2017 slides (1.3MB PDF )
Title: Clinical Activity of Adenosine A2a Receptor (A2aR) Inhibitor CPI-444 is Associated with Tumor Expression of Adenosine Pathway Genes and Tumor Immune Modulation
Presenter: Jason J. Luke, M.D., FACP, Assistant Professor of Medicine, University of Chicago Medicine
Session: Clinical Trials: Novel Combinations
Presentation Date and Time: November 11, 2017, 5:45 - 6:00 p.m. EST


2017 Corvus R&D Day Update – The Adenosine Pathway: Extending the Reach of Cancer Immunotherapy

PRESENTATION SLIDES

Slides: The Adenosine Pathway: Extending the Reach of Cancer Immunotherapy (12MB PDF)
Presentation Date and Time: Tuesday, July 11, 2017, 9:00 a.m. – 12:00 p.m. ET


2017 American Society of Clinical Oncology (ASCO) Annual Meeting

ASCO ORAL PRESENTATION

Abstact #: 3004 (2MB PDF )
Title: Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients
Presenter: Lawrence Fong, M.D., Leader, Cancer Immunotherapy Program, Co-Director, Parker Institute of Cancer Immunotherapy at University of California, San Francisco
Presentation Date and Time: Monday, June 5, 2:27 p.m. CT
Location: Hall D1


2017 American Association for Cancer Research (AACR) Annual Meeting

ORAL PRESENTATIONS

Abstract #: CT119 (2MB PDF)
Title: CPI-444, an oral adenosine A2a receptor (A2AR) antagonist, demonstrates clinical activity in patients with advanced solid tumors  
Presenter: Leisha Emens, M.D., Ph.D., associate professor of oncology, John Hopkins Sidney Kimmel Comprehensive Cancer Center
Session Type: Oral Plenary
Presentation Date And Time: Tuesday, April 4, 10:30 a.m.-12:45 p.m. ET
Location: Ballroom C, Level 3, Washington Convention Center

POSTER PRESENTATIONS

Abstact #: 5593/Poster #: 25 (10MB PDF)
Title: Inhibition of A2AR induces anti-tumor immunity alone and in combination with anti-PD-L1 in preclinical and clinical studies
Presenter: Stephen Willingham, Ph.D., Corvus Pharmaceuticals 
Presentation Date and Time: Wednesday, April 5, 8:00 a.m-12:00 p.m. ET
Location: Convention Center, Halls A-C, Poster Section 24

Abstact #: 5598/Poster #: 30 (50K PDF)
Title: Adenosine signaling through A2AR limits the efficacy of anti-CTLA4 and chemotherapy in preclinical models
Presenter: Po Y. Ho, Corvus Pharmaceuticals 
Presentation Date and Time: Wednesday, April 5, 8:00 a.m-12:00 p.m. ET
Location: Convention Center, Halls A-C, Poster Section 24

Abstact #: 5577/Poster #: 9 (7MB PDF)
Title: A novel CD73-blocking antibody reduces production of immunosuppressive adenosine and restores T-cell function
Presenting Author: Emily Piccione, Ph.D., Corvus Pharmaceuticals 
Presentation Date and Time: Wednesday, April 5, 8:00 a.m.-12:00 p.m. ET
Location: Convention Center, Halls A-C, Poster Section 24